SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class

BACKGROUND: For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti...

全面介紹

Na minha lista:
書目詳細資料
發表在:BMC Endocr Disord
Main Authors: Schernthaner, Guntram, Drexel, Heinz, Moshkovich, Evgeny, Zilaitiene, Birute, Martinka, Emil, Czupryniak, Leszek, Várkonyi, Tamás, Janež, Andrej, Ducena, Kristine, Lalić, Katarina, Tankova, Tsvetalina, Prázný, Martin, Smirčić Duvnjak, Lea, Sukhareva, Olga, Sourij, Harald
格式: Artigo
語言:Inglês
出版: BioMed Central 2019
主題:
Correspondence
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6580491/
https://ncbi.nlm.nih.gov/pubmed/31208401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12902-019-0387-y
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍